Gastroesophageal reflux disease

Current Opinion in Pharmacology

Volumn 5, Issue 6 SPEC. ISS., 2005, Pages 589-595

  Armstrong, David ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALGINIC ACID; ANTACID AGENT; AZD 0865; BACLOFEN; BENATOPRAZOLE; CISAPRIDE; CYCLOOXYGENASE 2 INHIBITOR; DOMPERIDONE; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; ITOPRIDE; METOCLOPRAMIDE; MOSAPRIDE; OMEPRAZOLE; PANTOPRAZOLE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; REVAPRAZAN; SEROTONIN 4 AGONIST; SORAPRAZAN; STOMACH SECRETION INHIBITOR; TEGASEROD; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ANTIREFLUX OPERATION; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ENDOSCOPIC SURGERY; ESOPHAGOGASTRODUODENOSCOPY; ESOPHAGUS INJURY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; HEALING; HUMAN; MEDICAL DOCUMENTATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY;

EID: 27744508500     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2005.09.001     Document Type: Review

References (41)

1. J. Dent H.B. El-Serag M-A. Wallander S. Johansson Epidemiology of gastro-oesophageal reflux disease: A systematic review Gut 54 2005 710-717
2. A.B. Thomson A.N. Barkun D. Armstrong N. Chiba R.J. White S. Daniels S. Escobedo B. Chakraborty P. Sinclair S.J. Van Zanten The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: The Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study Aliment Pharmacol Ther 17 2003 1481-1491
3. D. Armstrong J.K. Marshall N. Chiba R. Enns C.A. Fallone R. Fass R. Hollingworth R.H. Hunt P.J. Kahrilas S. Mayrand P. Moayyedi W.G. Paterson D. Sadowski S.J. van Zanten Canadian Association of Gastroenterology GERD Consensus Group. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004 Can J Gastroenterol 19 2005 15-35
4. N. Chiba C.J. De Gara J.M. Wilkinson R.H. Hunt Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis Gastroenterology 112 1997 1798-1810
5. B. van Pinxteren M. Numans J. Lau N.J. de Wit A.P.S. Hungin P.A.L. Bonis Short-term treatment of gastroesophageal reflux disease. A systematic review and meta-analysis of the effect of acid-suppressant drugs in empirical treatment and in endoscopy-negative patients J Gen Intern Med 18 2003 755-763
6. D. Armstrong Review article: Gastric pH - the most relevant predictor of benefit in reflux disease? Aliment Pharmacol Ther 20 Suppl 5 2004 19-26
7. P.J. Kahrilas G.W. Falk D.A. Johnson C. Schmitt D.W. Collins J. Whipple D. D'Amico B. Hamelin B. Joelsson for the Esomeprazole Study Investigators Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomized controlled trial. The Esomeprazole Study Investigators Aliment Pharmacol Ther 14 2000 1249-1258
8. J.E. Richter P.J. Kahrilas J. Johanson P. Maton J.R. Breiter C. Hwang V. Marino B. Hamelin J.G. Levine Esomeprazole Study Investigators Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial Am J Gastroenterol 96 2001 656-665
9. D.O. Castell P.J. Kahrilas J.E. Richter N.B. Vakil D.A. Johnson S. Zuckerman W. Skammer J.G. Levine Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis Am J Gastroenterol 97 2002 575-583
10. J. Labenz D. Armstrong K. Lauritsen P. Katelaris S. Schmidt K. Schutze G. Wallner H. Juergens H. Preiksaitis N. Keeling et al. EXPO Study Investigators. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: The EXPO study Aliment Pharmacol Ther 21 2005 739-746
11. M.B. Fennerty J.F. Johanson C. Hwang M. Sostek Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis Aliment Pharmacol Ther 21 2005 455-463
12. P.O. Katz D.O. Castell Y. Chen T. Andersson M.B. Sostek Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: A randomized, three-way crossover study Aliment Pharmacol Ther 20 2004 399-406
13. L. Lundell P. Miettinen H.E. Myrvold S.A. Pedersen B. Liedman J.G. Hatlebakk R. Julkonen K. Levander J. Carlsson M. Lamm I. Wiklund Continued (5-Year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease J Am Coll Surg 192 2001 172-181
14. 2-RA-start' management strategies in primary care-the CADET-HR Study Aliment Pharmacol Ther 21 2005 1189-1202
15. 2 RA therapy on nocturnal gastric acid breakthrough Gastroenterology 122 2002 625-632
16. T. Ours W. Fackler J. Richter M. Vaezi Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure Am J Gastroenterol 98 2003 545-550
17. J. Galmiche P. Barthelemy B. Hamelin Treating the symptoms of gastro-oesophageal reflux disease: A double-blind comparison of omeprazole and cisapride Aliment Pharmacol Ther 11 1997 765-773
18. S. Vigneri R. Termini G. Leandro S. Badalamenti M. Pantalena V. Savarino F. Di Mario G. Battaglia G.S. Mela A. Pilotto et al. A comparison of five maintenance therapies for reflux esophagitis N Engl J Med 333 1995 1106-1110
19. +)-ATPase by proton pump inhibitors J Am Chem Soc 126 2004 7800-7811
20. R.J.F. Laheij M.C.J.M. Sturkenboom R.J. Hassing J. Dieleman B.H.C. Stricker J.B.M.J. Jansen Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs J Am Med Assoc 292 2004 1955-1960
21. S. Dial K. Alrasadi C. Manoukian A. Huang D. Menzies Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: Cohort and case-control studies Can Med Assoc J 171 2004 33-38
22. B agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors Gut 52 2003 1397-1402
23. R. Ouatu-Lascar R.C. Fitzgerald G. Triadafilopoulos Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression Gastroenterology 117 1999 327-335
24. H.B. El-Serag T.V. Aguirre S. Davis M. Kuebeler A. Bhattacharyya R.E. Sampliner Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus Am J Gastroenterol 99 2004 1877-1883
25. H.B. El-Serag T. Aguirre M. Kuebeler R.E. Sampliner The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy Aliment Pharmacol Ther 19 2004 1255-1260
26. J.A. Jankowski M. Anderson Review article: Management of oesophageal adenocarcinoma - control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus Aliment Pharmacol Ther 20 Suppl 5 2004 71-80
27. J.P. Galmiche S. Sacher-Huvelin S. Bruley des Varannes F. Vavasseur A. Taccoen P. Fiorentini M. Homerin A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers Aliment Pharmacol Ther 21 2005 575-582
28. J.P. Galmiche S. Bruley Des Varannes P. Ducrotte S. Sacher-Huvelin F. Vavasseur A. Taccoen P. Fiorentini M. Homerin Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: Effects on intragastric pH and comparison with esomeprazole in healthy volunteers Aliment Pharmacol Ther 19 2004 655-662
29. R.H. Hunt D. Armstrong C. James S.K. Chowdhury Y. Yuan P. Fiorentini A. Taccoen P. Cohen Effect on intragastric pH of a PPI with a prolonged plasma half-life: Comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers Am J Gastroenterol 100 2005 1949-1956
30. N. Vakil Review article: New pharmacological agents for the treatment of gastro-oesophageal reflux disease Aliment Pharmacol Ther 19 2004 1041-1049
31. J. Mössner K. Caca Review: Developments in the inhibition of gastric acid secretion Eur J Clin Invest 35 2005 469-475
32. T. Lind T. Havelund L. Lundell H. Glise K. Lauritsen S.A. Pedersen O. Anker-Hansen A. Stubberod G. Eriksson R. Carlsson O. Junghard On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial Aliment Pharmacol Ther 13 1999 907-914
33. P.J. Kahrilas E.M. Quigley D.O. Castell S.J. Spechler The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastroesophageal reflux disease Aliment Pharmacol Ther 14 2000 1503-1509
34. Y.S. Kim T.H. Kim C.S. Choi Y.W. Shon S.W. Kim G.S. Seo Y.H. Nah M.G. Choi S.C. Choi Effect of itopride, a new prokinetic, in patients with mild GERD: A pilot study World J Gastroenterol 11 2005 4210-4214
35. K. Madan V. Ahuja P.C. Kashyap M.P. Sharma Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: A randomized trial Dis Esophagus 17 2004 274-278
36. C. van Rensburg K. Bardhan No clinical benefit of adding cisapride to pantoprazole for treatment of gastro-oesophageal reflux disease Eur J Gastroenterol Hepatol 13 2001 909-914
37. M.A. van Herwaarden M. Samsom H. Rydholm A.J. Smout The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease Aliment Pharmacol Ther 16 2002 1655-1662
38. M.F. Vela R. Tutuian P.O. Katz D.O. Castell Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH Aliment Pharmacol Ther 17 2003 243-251
39. A.F. Ciccaglione L. Marzio Effect of acute and chronic administration of the GABAB agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease Gut 52 2003 464-470
40. C. Hur N.S. Nishioka G.S. Gazelle Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus J Natl Cancer Inst 96 2004 316-325
41. J. Jankowski P. Moayyedi Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus J Natl Cancer Inst 96 2004 885-887